The availability, price and affordability of antidiabetic drugs in Hubei province, China

Health Policy and Planning

Volumn 33, Issue 8, 2018, Pages 937-947

  Gong, Shiwei ^a   Cai, Hongbing ^a   Ding, Yufeng ^a   Li, Weijie ^a   Juan, Xu ^a   Peng, Jinlan ^a   Jin, Si ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

affordability; Antidiabetic drugs; availability; China; markup; price

Indexed keywords

ANTIDIABETIC AGENT; ESSENTIAL DRUG; GENERIC DRUG;

CHINA; COMMERCIAL PHENOMENA; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ECONOMICS; HEALTH CARE DELIVERY; HUMAN; SUPPLY AND DISTRIBUTION;

CHINA; COMMERCE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DRUGS, ESSENTIAL; DRUGS, GENERIC; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 85054455492     PISSN: 02681080     EISSN: 14602237     Source Type: Journal    
DOI: 10.1093/heapol/czy076     Document Type: Article

References (28)

1. Abidi A, Rizvi DA, Ahmad A. 2016. Pharmacoeconomic and drug utilization study of antidiabetic therapy in a tertiary care teaching hospital of northern India. Asian Journal of Pharmaceutical and Clinical Research 9: 371-5.
2. Alcorn T, Ouyang YD. 2012. Diabetes saps health and wealth from China's rise. The Lancet 379: 2227-8.
3. Bragg F, Holmes MV, Iona A et al. 2017. Association between diabetes and cause-specificmortality in rural and urban areas of China. JAMA 317: 280-9.
4. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. 2009. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. The Lancet 373: 240-9.
5. Dabare PR, Wanigatunge CA, Beneragama BH. 2014. A national survey on availability, price and affordability of selected essential medicines for non communicable diseases in Sri Lanka. BMC Public Health 14: 817. Editor. 2014. Diabetes in China: mapping the road ahead. Lancet Diabetes and Endocrinology 2: 923.
6. Ewen M, Zweekhorst M, Regeer B, Laing R. 2017. Baseline assessment of WHO's target for both availability and affordability of essential medicines to treat non-communicable diseases. PLoS One 12: e0171284.
7. Fang Y, Wagner AK, Yang S et al. 2013. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China. The Lancet Global Health 1: e227-37.
8. Gong S, Wang Y, Pan X et al. 2016. The availability and affordability of orphan drugs for rare diseases in China. Orphanet Journal of RareDiseases 11: 20.
9. Huang Y, Vemer P, Zhu J, Postma MJ, Chen W. 2016. Economic burden in Chinese patients with diabetes mellitus using electronic insurance claims data. PLoS One 11: e0159297.
10. Hubei Provincial Bureau of Statistics, China. 2016. Hubei Statistical Yearbook. Available at: http://data.hb.stats.cn/CityData.aspx?DataType= 67&ReportType=3, accessed 1 October 2017.
11. Hubei Provincial Government, China. 2016. Drug centralized bidding platform. Available at: http://jy.hbjycg.com/ProcureCatalogList1.aspx, accessed 1 August 2016.
12. International Diabetes Federation. 2015. IDF diabetes atlas, available at: http://www.diabetesatlas.org/, accessed 1 October 2015.
13. Jiang M, Yang S, Yan K et al. 2013. Measuring access to medicines: a survey of prices, availability and affordability in Shaanxi province of China. PLoS One 8: e70836.
14. Jiang M, Zhou Z, Wu L et al. 2015. Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future. International Journal of Clinical Pharmacy 37: 12-7.
15. Liu C, Zhang X, Liu C, Ewen M, Zhang Z, Liu G. 2017. Insulin prices, availability and affordability: a cross-sectional survey of pharmacies in Hubei Province, China. BMC Health Services Research 17: 597.
16. Luo Wanqiao DQ, Wensheng L. 2015. Status of multi-level medical insurance system's safeguard for diabetics and study on its expense compensation mechanism. Chinese Journal of Medical Management Sciences 5: 34-7.
17. Sun J, Ren L, Wirtz V. 2016. How Essential the anti-diabetic medications in Chinese hospitals? China Pharmacy 19: 881-19.
18. Susanne Gelders ME, Noguchi N, Laing R. 2006. Price, availability and affordability. An international comparison of chronic disease medicines, available at: http://apps.who.int/iris/bitstream/10665/116493/1/dsa560. pdf, accessed 1 August 2006.
19. Wang Qi-hang LR, Feng-xia L
20. WHO Collaborating Centre for Drug Statistics Methodology, 2016. ATC/DDD index 2016, available at: https://www.whocc.no/atcdddindex/ , accessed 20 December 2016.
21. World Health Organization, 2008. Measuring medicine prices, availability, affordability and price components, available at: http://www.who.int/medi cines/areas/access/OMSMedicineprices.pdf? ua1, accessed 1 August 2008.
22. World Health Organization, 2016. Global report on diabetes, available at: http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257eng. pdf? ua1, accessed 1 October 2016.
23. Xi X, Li W, Li J et al. 2015. A survey of the availability, prices and affordability of essential medicines in Jiangsu Province, China. BMC Health Services Research 15: 345.
24. Xu Y, Wang L, He J et al. 2013. Prevalence and control of diabetes in Chinese adults. JAMA 310: 948-59.
25. Yang H, Dib HH, Zhu M, Qi G, Zhang X. 2010. Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China. Health Policy and Planning 25: 219-29.
26. Yang W, Zhao W, Xiao J et al. 2012. Medical care and payment for diabetes in China: enormous threat and great opportunity. PLoS One 7: e39513.
27. Zhou M, Astell-Burt T, Bi Y et al. 2015. Geographical variation in diabetes prevalence and detection in china: multilevel spatial analysis of 98, 058 adults. Diabetes Care 38: 72-81.
28. Zhu Wenwen YCC, Wenfang S, Qian W et al. 2017. Study on availability evaluation of oral antidiabetic agents in public hospitals from Shaanxi Province. China Pharmacy 28: 596-9.